Does the number of doses matter? A qualitative study of HPV vaccination acceptability nested in a dose reduction trial in Tanzania.

Drug Tapering Female Humans Papillomavirus Infections / prevention & control Papillomavirus Vaccines Tanzania Vaccination
Acceptability Dose reduction HPV vaccination Qualitative Randomisation Trial participation

Journal

Tumour virus research
ISSN: 2666-6790
Titre abrégé: Tumour Virus Res
Pays: Netherlands
ID NLM: 101775149

Informations de publication

Date de publication:
12 2021
Historique:
received: 28 12 2020
revised: 30 04 2021
accepted: 18 05 2021
pubmed: 30 5 2021
medline: 27 1 2022
entrez: 29 5 2021
Statut: ppublish

Résumé

The multi-dose regimen is a known barrier to successful human papillomavirus (HPV) vaccination. Emerging evidence suggests that one vaccine dose could protect against HPV. While there are clear advantages to a single dose schedule, beliefs about vaccine dosage in low and middle income countries (LMICs) are poorly understood. We investigated acceptability of dose-reduction among girls, and parents/guardians of girls, randomised to receive one, two or three doses in an HPV vaccine dose-reduction and immunobridging study (DoRIS trial) in Tanzania. Semi-structured interviews with girls (n = 19), and parents/guardians of girls (n = 18), enrolled in the study and completing their vaccine course. Most participants said they entrusted decisions about the number of HPV vaccine doses to experts. Random allocation to the different dose groups did not feature highly in the decision to participate in the trial. Given a hypothetical choice, girls generally said they would prefer fewer doses in order to avoid the pain of injections. Parental views were mixed, with most wanting whichever dose was most efficacious. Nonetheless, a few parents equated a higher number of doses with greater protection. Vaccine trials and programmes will need to employ careful messaging to explain that one dose offers sufficient protection against HPV should emerging evidence from ongoing dose-reduction clinical trials support this.

Sections du résumé

BACKGROUND
The multi-dose regimen is a known barrier to successful human papillomavirus (HPV) vaccination. Emerging evidence suggests that one vaccine dose could protect against HPV. While there are clear advantages to a single dose schedule, beliefs about vaccine dosage in low and middle income countries (LMICs) are poorly understood. We investigated acceptability of dose-reduction among girls, and parents/guardians of girls, randomised to receive one, two or three doses in an HPV vaccine dose-reduction and immunobridging study (DoRIS trial) in Tanzania.
METHODS
Semi-structured interviews with girls (n = 19), and parents/guardians of girls (n = 18), enrolled in the study and completing their vaccine course.
RESULTS
Most participants said they entrusted decisions about the number of HPV vaccine doses to experts. Random allocation to the different dose groups did not feature highly in the decision to participate in the trial. Given a hypothetical choice, girls generally said they would prefer fewer doses in order to avoid the pain of injections. Parental views were mixed, with most wanting whichever dose was most efficacious. Nonetheless, a few parents equated a higher number of doses with greater protection.
CONCLUSION
Vaccine trials and programmes will need to employ careful messaging to explain that one dose offers sufficient protection against HPV should emerging evidence from ongoing dose-reduction clinical trials support this.

Identifiants

DOI: 10.1016/j.tvr.2021.200217 PMID: 34051389 PMC: PMC8233223
pubmed: 34051389
pii: S2666-6790(21)00007-0
doi: 10.1016/j.tvr.2021.200217
pmc: PMC8233223
pii:
doi:

Substances chimiques

Papillomavirus Vaccines 0

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

200217

Subventions

Organisme : Chief Scientist Office
ID : SPHSU11
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N006135/1
Pays : United Kingdom
Organisme : Chief Scientist Office
ID : SPHSU18
Pays : United Kingdom
Organisme : Chief Scientist Office
ID : SPHSU18
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_1,201,711
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12017/11
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00022/3
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R010161/1
Pays : United Kingdom

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.

Auteurs

K R Mitchell (KR)

MRC/CSO Social and Public Health Sciences Unit, University of Glasgow, Berkeley Square, 99 Berkeley St, Glasgow, G3 7HR, UK. Electronic address: kirstin.mitchell@glasgow.ac.uk.

T Erio (T)

Mwanza Intervention Trials Unit, National Institute of Medical Research, Isamilo, Mwanza, Tanzania. Electronic address: tusajigwe.erio@gmail.com.

H S Whitworth (HS)

Mwanza Intervention Trials Unit, National Institute of Medical Research, Isamilo, Mwanza, Tanzania; Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK. Electronic address: Hilary.Whitworth@lshtm.ac.uk.

G Marwerwe (G)

Mwanza Intervention Trials Unit, National Institute of Medical Research, Isamilo, Mwanza, Tanzania. Electronic address: mutani.mwanagindu@mitu.or.tz.

J Changalucha (J)

Mwanza Intervention Trials Unit, National Institute of Medical Research, Isamilo, Mwanza, Tanzania. Electronic address: jchangalucha@yahoo.com.

K Baisley (K)

Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK. Electronic address: Kathy.Baisley@lshtm.ac.uk.

C J Lacey (CJ)

York Biomedical Research Institute & Hull York Medical School, University of York, John Hughlings Jackson Building, University Rd, Heslington, York YO10 5DD, UK. Electronic address: Charles.Lacey@hyms.ac.uk.

R Hayes (R)

Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK. Electronic address: Richard.Hayes@lshtm.ac.uk.

S de SanJosé (S)

Catalan Institute of Oncology, Avinguda de La Granvia de L'Hospitalet 199-203, 08908 L'Hospitalet de Llobregat (Barcelona), Spain. Electronic address: sdesanjose@path.org.

D Watson-Jones (D)

Mwanza Intervention Trials Unit, National Institute of Medical Research, Isamilo, Mwanza, Tanzania; Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK. Electronic address: Deborah.Watson-Jones@lshtm.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Diminution progressive de la dose du médicament › Does the number of doses matter? A qualitative...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Does the number of doses matter? A qualitative...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladies transmissibles › Maladies sexuellement transmissibles › Maladies sexuellement transmissibles virales › Infections à papillomavirus › Does the number of doses matter? A qualitative...
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins antiviraux › Vaccins contre les papillomavirus › Does the number of doses matter? A qualitative...
questionsmedicales.fr › Régions géographiques › Afrique › Afrique subsaharienne › Afrique de l'Est › Tanzanie › Does the number of doses matter? A qualitative...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Pratiques en santé publique › Prévention primaire › Immunisation › Vaccination › Does the number of doses matter? A qualitative...